Sentences with phrase «of pembrolizumab»

In fact, the Food and Drug Administration's approval of pembrolizumab in May 2017 for adult and pediatric patients with solid tumors and high microsatellite instability, was the first time it had approved a cancer treatment based on a genetic feature rather than the cancer's location of origin.

A phase Ib study of pembrolizumab (MK - 3475) in patients with advanced triple - negative breast cancer.

Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases.

«Interestingly, we found that activity of pembrolizumab was seen in both PD - L1 - positive and - negative tumors.

Alley and his team presented data from KEYNOTE - 028, an ongoing trial involving 13 different research sites in six different countries all looking at the effect of pembrolizumab on patients with advanced malignancies, including malignant pleural mesothelioma.

«KEYNOTE - 024 is the first phase III trial of pembrolizumab as first line treatment in patients with high PD - L1 expression, who represent 27 - 30 % of those with advanced NSCLC.»

These results support the use of pembrolizumab as the new standard of care for advanced bladder cancer,» concluded Dr Necchi.

With the recent presentation of the data from Keynote - 024, and the recent approval of pembrolizumab for high PD - L1 expressing tumors, the landscape of lung cancer oncology will change dramatically and for the better.

Of the 1483 patients in these KEYNOTE trials who had other forms of advanced melanoma and who received at least one dose of pembrolizumab, 33 % responded to the treatment, 72 % were still alive without their disease progressing and the median (average) overall survival time was nearly two years.

«We found that the combination of pembrolizumab and chemotherapies evaluated thus far — in patients with advanced small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC)-- appears to be safe,» said Dr. Glen Weiss, Director of Clinical Research and Medical Oncologist at CTCA ® at Western, where he currently supervises more than 30 clinical trials involving hundreds of patients.

Merck, the manufacturer of pembrolizumab, funded this clinical trial and provided Adams and her colleagues with research support.

KEYNOTE - 024 investigated the efficacy of pembrolizumab compared to standard of care with platinum - based chemotherapy in untreated patients with advanced NSCLC and high PD - L1 expression (defined as expression in at least 50 % of tumour cells).

Zakharia, who presented the data at the 2017 American Association for Cancer Research (AACR) Annual Meeting in Washington, DC, reveals the overall response data from the trial, toxicity data, and compares the results to historical data of pembrolizumab monotherapy from KEYNOTE - 006, which included similar patients.

Naiyer Rizvi, M.D., of Memorial Sloan Kettering, presented results of pembrolizumab in lung cancer.

Dr. Weiss» study of pembrolizumab was presented during a session on small cell lung cancer when the theme of the conference was Science Drives Lung Cancer Advances.

The FDA also expanded the approval of pembrolizumab to treat the majority of people with NSCLC who had received prior chemotherapy, greatly increasing the patient population that can benefit from the treatment.

Conversely, the side effects of pembrolizumab are much less frequent and more tolerable, says Adams.

Reporting the results from three trials of pembrolizumab for patients with advanced melanoma, Dr Marcus Butler, a medical oncologist at the Princess Margaret Cancer Centre, Toronto, Canada, told ECCO2017 that 84 of the 1567 patients in the KEYNOTE - 001, 002 and 006 studies had advanced mucosal melanoma.

Beginning with the first enrollees two years ago, doctors gave each patient a dose of pembrolizumab every two weeks.

Dr. Glen Weiss, M.D., M.B.A., is the first author of the study abstract: Phase Ib / II Study of Pembrolizumab plus Chemotherapy in Advanced Cancer: Results of lung cancer patients receiving (at least) 1 prior line of therapy.

A Phase I / II Study of Pembrolizumab (MK - 3475) in Children with Advanced Melanoma or a PD - L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma

In 2015 and 2016, the FDA expanded its approval of pembrolizumab and nivolumab as first - line treatments for unresectable or metastatic melanoma, regardless of mutational status.